NASDAQ •
Healthcare •
Drug Manufacturers - Specialty & Generic •
Quote as of 09/01/2026 16:00
Company Profile
IndustryDrug Manufacturers - Specialty & Generic
SectorHealthcare
ExchangeNASDAQ
Market Capitalization250 mln
Float92.07 mln
Earnings Date11/12/2026
Piotroski F-Score
3
/ 9
Below average
1-Year Forecast
8.50
Transformational upside
Relative Strength
94
/ 100
Top performer
Debt / Equity
0.00
Debt-free
ROE
-226
Deeply negative
Dividend Yield
0.00%
No dividend
Business Description
Cardiol Therapeutics is a Canadian clinical-stage company focused on developing treatments for serious heart conditions, including myocarditis, pericarditis, and heart failure. Its main drug candidate, CardiolRx, is currently being tested in a large international clinical trial to assess how well it works and how safe it is. The company is also working on an injectable treatment called CRD-38, which is in early-stage research for patients with heart failure. Founded in 2017 and based in Oakville, Ontario, Cardiol operates under a licensing agreement that supports its drug development efforts.
